NCT00314314View on ClinicalTrials.gov

The Effect of Intranasal Insulin on Neurocognitive Function in Euthymic Patients With Bipolar Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Bipolar Disorder
Interventions
DRUG

Intranasal Insulin

Intranasal spray; 40 IU qid; 8 weeks

DRUG

Diluent

Intranasal spray; 8 weeks

Trial Locations (1)

M5T 2S8

Toronto Western Hospital, Toronto

All Listed Sponsors
collaborator

Hamilton Health Sciences Corporation

OTHER

lead

University Health Network, Toronto

OTHER

NCT00314314 - The Effect of Intranasal Insulin on Neurocognitive Function in Euthymic Patients With Bipolar Disorder | Biotech Hunter | Biotech Hunter